Yuhan Research Institute, Yuhan Corporation, Yongin 17084, Republic of Korea; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Int J Pharm. 2018 Oct 25;550(1-2):160-169. doi: 10.1016/j.ijpharm.2018.08.038. Epub 2018 Aug 20.
The main purpose of this study was to develop gastroretentive tablets with floating and swelling properties for once-daily administration of pregabalin. The non-effervescent floating and swelling tablets were prepared using wet granulation and compaction, which are widely used and easily accessible. All formulations showed sustained release patterns and maintained buoyancy for over 24 h. The amount of hydroxypropyl methylcellulose and crospovidone were found to be critical factors affecting in vitro dissolution and floating properties of the prepared tablets. The optimized tablets containing 300 mg of pregabalin started to float within 3 min and swelled above 12.8 mm, the reported pyloric sphincter diameter during the fed state, in all dimensions including length, width, and thickness. In vivo results in beagle dogs indicated that the optimized formulations are suitable as once-daily dosage forms, and dose proportionality was observed in doses ranging from 75 to 300 mg. Additionally, the dogs administered with the formulation having poor in vitro gastroretentive properties showed highly variable and reduced extent of absorption, signifying the necessity of the gastroretentive drug delivery system. In conclusion, the developed non-effervescent floating tablets are promising candidates for once-daily delivery of pregabalin.
本研究的主要目的是开发具有漂浮和膨胀特性的胃滞留片,以便每日一次给予普瑞巴林。非泡腾型漂浮和膨胀片采用湿法制粒和压片制备,这两种方法应用广泛且易于获得。所有配方均显示出持续释放模式,并能维持超过 24 小时的浮力。发现羟丙甲纤维素和交联聚维酮的用量是影响所制备片剂体外溶出度和漂浮性能的关键因素。含有 300mg 普瑞巴林的优化片剂在 3 分钟内开始漂浮,并在所有尺寸(包括长度、宽度和厚度)上膨胀超过 12.8mm,这是在进食状态下报道的幽门括约肌直径。在比格犬体内的结果表明,优化配方适合作为每日一次的剂型,在 75 至 300mg 的剂量范围内观察到剂量比例性。此外,给予体外胃滞留性能差的制剂的犬表现出高度可变和降低的吸收程度,这表明需要胃滞留药物递送系统。总之,所开发的非泡腾型漂浮片剂是普瑞巴林每日一次给药的有前途的候选药物。